Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated September 05, 2025, titled ""Glenmark Initiates a Multi-Country Phase 3 Clinical Trial for Envafolimab in Resectable Stage III Non-Small Cell Lung Cancer"".